health information
Posts tagged Vaccine
Top 5 reasons why you should avoid the vaccine against seasonal flu in 2010
01 year ago
by admin
in Health Conditions
The flu season is upon us and it’s time to be afraid – but not because of the flu. This is the vaccine against seasonal flu, you should fear, as the vaccine against the flu is more dangerous than the flu itself!
Year after year, the flu season to a vicious circle with Big Pharma (Big Pharma), health authorities, with your doctor, and the public. Big Pharma is to promote the vaccine against seasonal influenza, health authorities, and your doctor will take a hit.
If you receive a vaccine against influenza for the 2010 season of the flu plan, here are five reasons why not to do in your interest to this:
1. Flu this season is just another flu. It can be fatal to those who already have very low immune system, but that is not the ruthless killer show that Big Pharma and the media often to be. CDC data showed that weekly were 34 end 29 August 2009, there 236 hospitalizations and 37 deaths associated with influenza in children. This represents only 5 children in the hospital and less than one death per state, and these numbers are not epidemic.
2 The current version of the vaccine against influenza is a combination vaccine against ordinary flu and the vaccine against swine flu. The swine flu fears turned out to be duds, but Big Pharma still want you, the vaccine against swine flu, adding it plans this year to meet regularly against influenza. Australia has the use of the new swine flu shot has components containing influenza in children under five years because the children of high fever, vomiting, cramps and fever have suffered.
A special government request that the vaccine showed last year’s swine flu, that the risk of diseases such as Guillain-Barre syndrome, a paralyzing disease increase tested autoimmune thrombocytopenia, a blood disease, not in the autoimmune blood enough can produce platelets and Bell’s palsy, a neurological reaction that causes facial paralysis.
3 The vaccine against seasonal flu is ineffective and may even be exposed to an increased risk of the flu. Many people go with the flu shortly after receiving a flu vaccine because the vaccine against seasonal flu, because the immune system weakens, allowing you more susceptible to flu.
The CDC data showed that among the 1148 flu virus from seasonal flu in the United States and other countries was 1143 (99.6 percent) were resistant to Tamiflu (oseltamivir), it is virtually worthless.
4 Children are overvaccinated. American children in particular, 49 received doses of 14 vaccines. Modern medicine can not explain why there is an explosion of diseases such as autism. The vaccines contain adjuvants -. Additives that increase the production of antibodies, such as mercury, aluminum and lead, your child’s development may influence
health authorities even pregnant women do on the vaccine against seasonal flu. One study showed that exposure of pregnant women flu virus trigger gene expression profile in the fetus is similar to autistic children as well.
5 Take control of your health is the best defense against influenza and other common diseases. A healthy lifestyle by eating well, exercising regularly and getting enough sleep and help manage your stress to the immune system – the body’s defense against the flu. Avoid sugar because it decreases your immune system almost immediately. Because influenza is a disease, you must reduce your hands always clean on the risk of spreading a virus to your nose, mouth or other.
Vaccine against influenza
Arbovax passport is an important milestone in the development of vaccine against dengue fever
01 year ago
by admin
in Health Conditions
ï »¿
Arbovax passport is an important milestone in the development of vaccine against dengue fever
Raleigh, NC (Business Wire) 14 October 2010
Arbovax, a company at an early stage of development of vaccines against diseases transmitted by insects to protect, has taken an important step in the development of a vaccine against dengue fever news with the successful completion of the non- human primate studies. The original study, which focused on dengue serotype 2 has already shown promising results and has the potential to provide protection at a dose? Unlike other technologies developed, the treatment with multiple doses. The test was carried out using the RxGen and Walter Reed Army Institute of
research.
Arbovaxâ? s unique strategy is based on the development of vaccines on their own host range mutation replicate the ability of the virus in different hosts based limits. This technology has been able Arbovax stable genetic modification of viruses to replicate efficiently in mammalian cells, the development of a strong immune response without creating the risk of the disease. Another advantage of the Arbovaxâ? The approach is that it produces very profitable.
â? We are very excited about these positive results at the beginning and move forward with the development of a product tetravalent â? States Malcolm Thomas, president and CEO of Arbovax. â? We believe that our new and unique approach represents a breakthrough in the development of vaccines that provide strong protection and durable with a single dose. In addition to protection against potentially fatal dengue fever, our technology was used to treat a variety of insect-borne viral diseases, including West Nile, yellow fever and Japanese> ????
of dengue
Dengue fever is a potentially fatal mosquito-borne virus. There was a significant increase in cases over the past sixty years on the basis of global climate change and rapid urbanization, the production of a dengue fever outbreak of major infectious diseases
Dengue haemorrhagic fever (DHF), a potentially lethal complication, was recognized 1950th
More than 2.5 billion people, two fifths of the world’s population, are now in danger.
The disease is now endemic in over 100 countries in Africa, the Americas, Eastern Mediterranean, Southeast Asia and Western Pacific.
In 2007 alone there were 890 000 reported cases of dengue fever in the Americas.
About 500,000 cases of DHF require hospitalization each year.
About 2.5% of those affected die, to be a high proportion of children.
Without proper treatment, DHF mortality exceeding 20%. About
Arbovax
Arbovax is in preclinical development of vaccines to protect against diseases that are committed transmitted by mosquitoes, which infect together more than 100 million people each year. Arbovaxâ? S original goal, dengue fever, second to malaria and tuberculosis by the World Health Organization for its devastating global impact. The company’s articles of association? S research and development led to three U.S. patents, which apply to all insect-borne viruses, including alphaviruses, bunyaviruses and flaviviruses. The company, in Raleigh, NC based, has more than 0,000 funding received from the North Carolina Biotechnology Center, and 0.5 million in Series A Financing
For further information on Arbovax and vaccine technology, please visit www.arbovax.com.
# # #
clear = “all”
class = “small-text”>
© Copyright 1997-2010, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Virus Protection
Breakthrough Vaccine to Treat Ovarian Cancer
81 year ago
by admin
in Health Care Services
ovarian cancer treatment
Cancer Treatment Centers of America develops patient-specific vaccine therapy Medical experts say more than 15-thousand women will die this year from ovarian cancer. But there is hope for those stricken with the disease in the form of a promising new vaccine. The breakthrough treatment, created by Cancer Treatment Centers of America and AVAX Therapeutics, Inc., uses the patient’s own tumor tissues to create a patient-specific vaccine. Combined with local chemotherapy, the treatment avoids stressing the patient’s immune system and, therefore, helps to increase the vaccine’s effectiveness. Ovarian cancer is a complex disease — it’s difficult to diagnose and often resistant to chemotherapy. The treatment will be available to women whose cancer has recurred after chemotherapy. Cancer Treatment Centers of America expects to begin treating patients this summer. please courtesy Cancer Treatment Centers of America
Vaccine against bird flu is almost ready to go to market
01 year ago
by admin
in Health Conditions
A spokesman announced
World Health Organization, that scientists have finally created an effective vaccine against influenza as possible.
Clinical trials with a vaccine against influenza, made by Sanofi Pasteur. The conclusions were that it took two injections of the vaccine administered distance of four weeks to vaccinate at least 50% of the human organism.
The Director of the National Institute of Allergy and Infectious Diseases, said Anthony S. Fauci, he was very concerned about the new vaccine and thrilled the immune properties, also says he believes the testing is an important step in the attempt on the world to stop a possible global pandemic.
Currently, the Government of the United States stocks of just four million doses of H5N1 vaccine, but this amount is not sufficient for all persons in the event of a pandemic is declared to cover.
A solution to stretch the vaccine stored by use of the vaccine on immunity substance (adjuvant) to stimulate, and so this reduction in the amount of vaccine necessary to immunize the human body and to mitigate the effects of the vaccine.
Now there are clinical studies with the adjuvant substances to see how the immune response to vaccines.
John Treanor, MD, director of the Vaccine Evaluation Unit and treatment at the University of Rochester in New York, said that, as it turned out that they need a higher dose of H5N1 vaccine to promote wanted immunity, a vaccine against influenza normal Man was made surprised scientists suspect that in the first test of the vaccine.
The high dose of the vaccine against the bird flu has caused a kind of immune response, which was to protect people in 1997 known case of an outbreak of H5N1 in Hong Kong.
Scientists are not sure whether the vaccine is effective in cases of human transmission of the virus, and they are not willing to expose the volunteers in the study of potentially deadly bird flu.
In developing much faster for new vaccines against avian influenza, the U.S. government supports producers to spend more and more vaccine in chicken eggs, the acceleration of cell culture techniques.
It is very important for manufacturers to produce new vaccines to accelerate, because the H5N1 virus is rapidly changing to a more aggressive would cause a human pandemic.
The good news is that governments consider the storage of H5N1 vaccine and the scientists are ready to create new and improved vaccines in the case of the development of the virus.
So if you want to know more about the vaccine against the bird flu or even know the Asian bird flu, click on this link http://www.bird-flu-info-center.com/
Vaccine against influenza
The problems that we can still run even if a vaccine against bird flu Introduced
01 year ago
by admin
in Health Conditions
bird flu virus is constantly changing, as it genetically mutates. This makes the identification of a specific type of virus as the culprit absolutely impossible. For the same reason pharmaceutical preparations targeted a specific type of virus would be useless in case of influenza, caused by a virus modified derivative of the oldest known.
WHO maintains a Global Influenza Surveillance Network is 110 influenza centers in 83 countries and four WHO Collaborating Centres. Representative samples of patients with avian flu, as symptoms are collected and analyzed for avian influenza virus. The latest strains in circulation around the world are identified and made recommendations on the composition of the influenza vaccine. This is done in February and September each year. Following is the WHO guide for the strains in the vaccine strain choice if they are to be used in the vaccine, to the final vaccine is a long process can take up to 6-8 months. The new vaccine production begins immediately after the announcement of WHO strains. The strains are then subjected to quality tests. While all three strains are mixed, both influenza A and influenza B strain of one, in a single vaccine. It is now that the vaccine is packaged and transported to the sale and administration. The vaccine against the bird flu has its own side effects. Usually, showed redness and swelling;. Fever, vomiting, headache, sore throat and minutes are also found physical complaints in about 5% of casesCurrently, the total production capacity of the world about 300 million flu vaccines annually. And the world population around 6.5 billion! It is therefore evident that in the event of a pandemic can not all be vaccinated, unless we or stocks of vaccine or a state of war are made, the former is not possible, because changing the vaccine composition is constantly every year and would not be possible in the near future . For these reasons, if a pandemic occurs, then for a few months of departure, we will not vaccines against avian influenza are available and our only saving grace would not have be-drug measures.
The quantity of vaccine should be available to meet the health care system in the world, a clearly defined distribution plan and a reliable supply chain applications have. This level of distribution and administration of vaccines is just not feasible today. It is now clear that the amount of vaccine produced annually lost if the changes flu virus from year to year. But these drugs are manufactured to test and demonstrate the technical capability of the system is available. WHO reports that include the use of antiviral drugs and vaccines, the most effective measures against the threat of avian flu. But again, it is obvious that only the vaccination can not help the 6.5 billion population country. It’s just a desperate, of the measures that we can count. In the meantime, we must continue to improve public knowledge about preventive measures, continue to take all precautions to reduce the spread of the flu and keep looking for better ways to fight the virus.Vaccine against influenza
Is a universal flu vaccine for future pandemics stop?
01 year ago
by admin
in Health Conditions
to stop
The only hope for an influenza pandemic, as we now come before the vaccine against bird flu, a “universal” flu, we develop Innoculate against all influenza viruses.
This would also in the habit of the people a new flu shot every autumn. The European Union is funding a collaborative project called universal vaccine to produce a vaccine for people permanantly vaccinated against all strains of influenza A and B influenza. plan, the M2e domain of the M2 protein ion channel extracullular that in all influenza A-type focus maintained. This exceeds the M2 ectodomain consists of 23 amino acids. Walter Fiers, co-inventor of the process said: “The structure of the M2 protein is nearly identical in all known flu virus can be transmitted between people.” previous vaccines focus on hemagglutinin (H) and neuraminidase protein (N) protein spikes that are coming out of the fatty sheath around the 8 subjects of the influenza virus. However, tests showed that the M2 protein remained relatively constant since the influenza virus was first isolated in 1933. schedule, the vaccine using recombinant bacterial fermentation to produce faster, cheaper and more efficient than conventional techniques flu always eggshope you human studies begin in spring 2007
included in the vaccine are universal: .. Arexis AB, Sweden; Pepscan Systems BV, Netherlands; Proxima Concepts Ltd., England. Eurogentec SA, Belgium, Flanders Interuniversity Institute for Biotechnology VZW (VIB), Belgium and the University of Gothenburg (UGOT), Sweden
Merck is also working on a universal vaccine based targeting M2.
San Diego-based Vical Incorporated is working on a vaccine against H5N1, and believes he held on to the keys to a vaccine against pandemic flu They have their vaccine, which focuses on three bits of DNA: .. the H5 protein, the nucleoprotein (NP) and matrix protein, the M2Using
conserved protein internal nucleoprotein (NP) raises a different kind of immunity. It is the type of T-cell-based called cytotoxic T lymphocytes (CTL) rather than antibodies. These CTL kill cells infected with influenza virus.
Rats and ferrets vaccinated with this vaccinenot only contact with H5N1 survived, but usually the human influenza virus as well.
L Israeli companies BiondVax Pharmaceuticals is working on a universal flu vaccination for two years. Their vaccine is inhaled, and they expect protection from 95% of all flu offer, including H5N1, and that the protection for a period of five years. Your vaccine based on 15 years of research by Weizmann Institute Professor Ruth Arnon. She worked on the search for conserved epitopes, fragments of the outer shell of the virus that never change, despite the antigenic shift and drift. She found that hemaggluttin hid a peptide that is fixed. BiondVax expected development time to take three to four years, much shorter if an avian flu pandemic hits. “Dr. Arnon decided to not to pursue a specific strain of the virus, she said:” We will identify the elements that duplicate for all influenza virus The use of genetic engineering, these common parts of the virus, and create a vaccine, -. no matter what virus will -. to get vaccinated, “said one of the founders of DevashBiondVax
One thing we based on universal vaccine M2 protein has to understand, however, is that we are still sick. This is because our body produces antibodies to bind M2 cells produce that’re already infected and to promote their game from the body, but not prevent them infected in the first place.
This influenza virus can infect even enter your body and lungs. However, the infection do not spread as easily. You can always ill, but probably not die. vaccines against neuro internal protein NP -. the same problem, they promote the killing of infected cells, but did not prevent infectionsVaccine against influenza
Trial vaccine for clinical treatment of ovarian cancer Centers of America
01 year ago
by admin
in Health Care Services
Chicago, IL (Vocus) 30 May 2008
Cancer Treatment Centers of America (CCTA), a leading provider of innovative anti-cancer therapies for patients with complex and advanced disease, has begun accepting patients for the trial of a vaccine against ovarian cancer clinics. Phase I / II, recently reviewed and approved by the U.S. Food and Drug Administration (FDA), will evaluate the safety and effectiveness of individual therapies for ovarian cancer vaccine to a maximum of 42 patients with chemotherapy-resistant advanced ovarian cancer.
The study will be conducted exclusively at CTCA at Midwestern Regional Medical Center in suburban Chicago. Join CTCA, patients with stage III or IV ovarian cancer who have tumor progression despite at least one but not more than two chemotherapy regimens. The participants in the clinical trial must first directly from surgical intervention at CTCA at Midwestern Regional Medical Center and localized chemotherapy into the abdominal cavity (intraperitoneal chemotherapy), infused a standard of cancer treatment available to many patients, CTCA. Patients are eligible for the study vaccine against cancer of the ovary, where it is clear that tumor cells are harvested enough debulked tumor to create a vaccine against ovarian cancer and the vaccine has passed rigid quality control.
AVAX Technologies to work with
CTCA, Inc., a vaccine against ovarian tumor cells with custom-made by each patient were surgically removed to create CTCA. These cells will be amended in AVAX laboratories and will be developed to produce an immune response against cancer of the ovaries to treat the patient.
awareness
“The systematic use of a vaccine for the patient’s immune system to combat their own tumors following localized, high-dose chemotherapy struggle not yet been attempted before,” said Donald Braun, Ph.D., CTCA vice president for clinical research. Sybilann Brown and Mr. Williams, a gynecologist-oncologist and surgeon at CTCA collaboration with Dr. David Berd, Chief Medical Officer of AVAX, will serve as investigators.
“CTCA offers a powerful combination of traditional and innovative therapies by a team of cancer specialists who work with each patient to determine the desired combination of therapies against cancer, fight, Dr. Williams.” Ovarian cancer is a complex disease that is often resistant to chemotherapy, radiation therapy and surgery. CTCA offer our patients the opportunity to participate in another landmark step in the fight against ovarian cancer. “
The American Cancer Society
ovarian cancer is considered the eighth most common cancer in women, and is the fifth leading cause of cancer death in women. It is estimated that there are 21 650 new cases of ovarian cancer in the United States in 2008 and 15 520 deaths from cancer. Ovarian cancer affects about one in 69 women after the National Alliance of ovarian cancer.
“We are thrilled, received FDA approval to begin this important clinical study and the opportunity it gives us will work with CTCA,” stated Dr. Berd AVAX. “Obviously, better treatment options for ovarian cancer needs and we hope that the vaccine eventually his place as a relatively nontoxic alternative treatment for these patients.”
More information about the vaccine trial is ovarian cancer, ovarian cancer and treatment will be found on CancerCenter.com. The patients in the clinical study is interested, a CTCA Oncology Information Specialist at cancer treatment center of America: Technologies, Inc.: ###
clear = “all”
founded in 1988, is Cancer Treatment Centers of America (CCTA) is a network of hospitals and cancer treatment community oncology programs in Illinois, Oklahoma, Pennsylvania and Washington – is to a site Future of Arizona is expected to open in spring 2009. CTCA provides a comprehensive treatment model, the patient is the center that integrates fully conventional, state-of-the-art medical treatments with scientific support complementary therapies such as nutrition, naturopathy, psychological counseling, physical therapy and spiritual support to meet specific, whole-person needs of cancer patients and complex diseases at an advanced stage. CTCA encourages patients and their families participate in treatment decisions through its Patient Empowerment Model MedicineSM. go for more information about cancer Centers of America to cancercenter.com.
About AVAX
AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The company is in research, clinical development and commercialization of biological products and therapies for cancer. In addition, the company provides contract manufacturing of biological products for other pharmaceutical and biotechnology companies.
P
Treatment of ovarian cancer
Vaccination is Not Immunization – Vaccine Facts Exposed
01 year ago
by admin
in Health Conditions
Vaccination is Not Immunization – Vaccine Facts Exposed
Doctor’s new book informs parents about vaccine risks, the real connection with autism, the swine flu scam & more. Ends the confusion once and for all on whether they should vaccinate or not. Many doctor testimonials.
Vaccination is Not Immunization – Vaccine Facts Exposed
Vaccine Risks Report.
01 year ago
by admin
in Health Conditions
Vaccine Risks Report.
65% Commission-affiliates: Toxic Ingredients, Side Effects, Autism & Mercury, Know Your Rights & Choices!
Vaccine Risks Report.
HIV vaccines against HIV / reactivity uninfected recipients vaccine against HIV-induced [Original]
01 year ago
by admin
in Health Care Services
Vaccine-Induced HIV Seropositivity/Reactivity in Noninfected HIV Vaccine Recipients [Original Contribution]
Context Induction of protective anti–human immunodeficiency virus (HIV) immune responses is the goal of an HIV vaccine. However, this may cause a reactive result in routine HIV testing in the absence of HIV infection. Objective To evaluate the frequency of vaccine-induced seropositivity/reactivity (VISP) in HIV vaccine trial participants. Design, Setting, and Participants Three common US Food …
Read more on Journal of the American Medical Association
